Spyre Therapeutics (SYRE) Research & Development: 2015-2025
Historic Research & Development for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to $45.2 million.
- Spyre Therapeutics' Research & Development rose 1.12% to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.5 million, marking a year-over-year increase of 21.58%. This contributed to the annual value of $162.8 million for FY2024, which is 81.88% up from last year.
- Per Spyre Therapeutics' latest filing, its Research & Development stood at $45.2 million for Q3 2025, which was up 12.71% from $40.1 million recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Research & Development registered a high of $50.5 million during Q4 2024, and its lowest value of $11.9 million during Q1 2021.
- Its 3-year average for Research & Development is $34.5 million, with a median of $34.9 million in 2024.
- Per our database at Business Quant, Spyre Therapeutics' Research & Development dropped by 19.36% in 2022 and then skyrocketed by 153.54% in 2024.
- Spyre Therapeutics' Research & Development (Quarterly) stood at $16.8 million in 2021, then fell by 15.08% to $14.3 million in 2022, then surged by 136.35% to $33.7 million in 2023, then skyrocketed by 49.88% to $50.5 million in 2024, then increased by 1.12% to $45.2 million in 2025.
- Its Research & Development was $45.2 million in Q3 2025, compared to $40.1 million in Q2 2025 and $41.6 million in Q1 2025.